Inventor · disambiguated record
Ivelin Georgiev
Also filed as: GEORGIEV IVELIN · GEORGIEV IVELIN STEFANOV
21 granted patents·17 pending applications·80 citations·filing 2012–2025
93Inventor score
Top patents by PatentIndex Score
38 records- 0194US10035844B2Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope proteinUS HEALTH·Filed 2017·Granted Jul 31, 2018·6 cites·32 claims
- 0294US10017543B2Prefusion RSV F proteins and their useUS HEALTH·Filed 2014·Granted Jul 10, 2018·26 cites·58 claims
- 0393US11878998B2Prefusion RSV F proteins and their useUS HEALTH·Filed 2021·Granted Jan 23, 2024·2 cites·27 claims
- 0493US10961283B2Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigensUS HEALTH·Filed 2017·Granted Mar 30, 2021·11 cites·34 claims
- 0593US10400015B2Recombinant HIV-1 envelope proteins and their useUS HEALTH·Filed 2015·Granted Sep 3, 2019·10 cites·51 claims
- 0692US11939356B2Self-assembling insect ferritin nanoparticlesUS HEALTH·Filed 2021·Granted Mar 26, 2024·2 cites·19 claims
- 0791US9695230B2Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope proteinUS HEALTH·Filed 2012·Granted Jul 4, 2017·9 cites·41 claims
- 0890US11459360B2Recombinant HIV-1 envelope proteins and their useUS HEALTH·Filed 2019·Granted Oct 4, 2022·4 cites·30 claims
- 0989US2025368690A1Prefusion rsv f proteins and their useTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVIC·Filed 2024·Application pending·0 cites
- 1087US12275758B2Prefusion RSV F proteins and their useUS HEALTH·Filed 2024·Granted Apr 15, 2025·0 cites·29 claims
- 1187US11981707B2Prefusion RSV F proteins and their useUS HEALTH·Filed 2023·Granted May 14, 2024·0 cites·25 claims
- 1287US11130785B2Prefusion RSV F proteins and their useUS HEALTH·Filed 2018·Granted Sep 28, 2021·2 cites·24 claims
- 1386US11174292B2Substitutions-modified prefusion RSV F proteins and their useUS HEALTH·Filed 2017·Granted Nov 16, 2021·2 cites·35 claims
- 1484US9475862B2Neutralizing GP41 antibodies and their useUS HEALTH·Filed 2012·Granted Oct 25, 2016·6 cites·22 claims
- 1580US12145968B2Recombinant HIV-1 envelope proteins and their useUS HEALTH·Filed 2022·Granted Nov 19, 2024·0 cites·13 claims
- 1675US2022002351A1Prefusion rsv f proteins and their useTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVIC·Filed 2021·Application pending·0 cites
- 1770US2025388627A1Prefusion rsv f proteins and their useTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVIC·Filed 2025·Application pending·0 cites
- 1869US2025102520A1Simultaneous detection of antigens and antigen specific antibodies in a guinea pig model systemUNIV VANDERBILT·Filed 2024·Application pending·0 cites
- 1968US2025115898A1Systems and methods for simultaneous detection of antigens and ligands thereofUNIV VANDERBILT·Filed 2024·Application pending·0 cites
- 2067US2024307528A1Methods of boosting an immune response against hiv using commensal microbe antigensUNIV VANDERBILT·Filed 2024·Application pending·0 cites
- 2165US10815295B2Broadly neutralizing HIV-1 antibodies that bind to the CD4-binding site of the envelope proteinUS HEALTH·Filed 2018·Granted Oct 27, 2020·0 cites·6 claims
- 2265US9783595B2Neutralizing GP41 antibodies and their useUS HEALTH·Filed 2016·Granted Oct 10, 2017·0 cites·28 claims
- 2362US2024254216A1Variant library-coupled immunogenicity mapping of monoclonal antibody therapeuticsUNIV VANDERBILT·Filed 2024·Application pending·0 cites
- 2461US12043660B210E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their useUS HEALTH·Filed 2021·Granted Jul 23, 2024·0 cites·19 claims
- 2561US10047148B2Neutralizing GP41 antibodies and their useUS HEALTH·Filed 2017·Granted Aug 14, 2018·0 cites·25 claims
- 2656US2023145420A1Recombinant vaccines and methods of use thereofUNIV VANDERBILT·Filed 2021·Application pending·0 cites
- 2755US11236152B2Neutralizing antibodies to HIV-1 GP41 and their useUS HEALTH·Filed 2016·Granted Feb 1, 2022·0 cites·22 claims
- 2853US2025296987A1Rsv/hmpv cross-reactive antibodiesUNIV VANDERBILT·Filed 2025·Application pending·0 cites
- 2952US2024101646A1Sars-cov-2 coronavirus antibodies and uses thereofUNIV VANDERBILT·Filed 2022·Application pending·0 cites
- 3051US12331133B2Therapeutic antibodies for treating lung cancerUNIV VANDERBILT·Filed 2020·Granted Jun 17, 2025·0 cites·10 claims
- 3151US2023124977A1Cross-reactive antibodies and uses thereofUNIV VANDERBILT·Filed 2022·Application pending·0 cites
- 3251US2023322906A1Hiv-1 specific antibodies and uses thereofUNIV VANDERBILT·Filed 2023·Application pending·0 cites
- 3351US2023348571A1Cross-reactive coronavirus antibodies and uses thereofUNIV VANDERBILT·Filed 2021·Application pending·0 cites
- 3446US2025340861A1Display technology libra-seq and methods of use thereofUNIV VANDERBILT·Filed 2025·Application pending·0 cites
- 3541US2022185870A1Hiv/hcv cross-reactive antibodies and uses thereofUNIV VANDERBILT·Filed 2020·Application pending·0 cites
- 3641US2022315982A1Methods for identification of antigen binding specificity of antibodiesUNIV VANDERBILT·Filed 2020·Application pending·0 cites
- 3739US12416037B2Methods for identification of ligand-blocking antibodies and for determining antibody potencyUNIV VANDERBILT·Filed 2021·Granted Sep 16, 2025·0 cites·17 claims
- 3836US2021302422A1Systems and methods for simultaneous detection of antigens and antigen specific antibodiesUNIV VANDERBILT·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ivelin Georgiev files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →